Browse Biomedical Data Science

Current Research and Scholarly InterestsI'm interested in the challenges that arise in healthcare and biomedicine when applying machine learning to data-scarce and safety-critical settings. This broad interest motivates me to work on topics surrounding self-supervised learning and synthetic data.

Contact Info
anishii@stanford.edu

Marcus Oehlrich, PhD

Masters Student in Biomedical Data Science, admitted Autumn 2025

BioI am a Professor of Finance, Accounting, and Taxation at accadis University of Applied Sciences in Bad Homburg, Germany, and I advise on startups, business valuation, and corporate finance. My consulting projects range from small startups in biotechnology and M&A transactions in the pharmaceutical and biotech sectors to the preparation of the business plan for the IPO of an international music and movie production group.

During my business studies, I became interested in law and medicine (especially cancer research), which is why I continued my education in these fields (including a Master of Science in Pharmaceutical Medicine, a Certificate in Pharmaceutical Law, and an MPH at Harvard T.H. Chan School of Public Health). Subsequently, I have started the M.S. in Biomedical Data Science at the Department of Biomedical Data Science at Stanford University School of Medicine.

I also had the privilege of serving as the CEO of the Institute for German, European, and International Medical Law, Health Law, and Bioethics of the Universities of Heidelberg and Mannheim (IMGB) from 2005 to 2011. At accadis University of Applied Sciences, I am Head of the Health Care Management Research Group and responsible for the Master of Arts in International Health Care Management. From 2010 to 2020, I served as the Honorary Consul of the Republic of San Marino in Frankfurt, Germany.

Most of my publications (12 books and more than 70 articles) are related to business topics. However, I also authored three books on cancer "Internetkompass Krebs [Internet compass cancer]" (Springer 2001), "Recombinant humanized monoclonal antibody Trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2/neu proto-oncogene: A systematic review" (dissertation.de 2003) and "Krebs vorbeugen und bekämpfen [Preventing and combating cancer: All about prevention, early detection, therapy]" (Reader's Digest 2012). The latter was translated into Polish, Czech, Croatian, Slovenian, and Hungarian.